RM 1812
Alternative Names: RM1812Latest Information Update: 31 Dec 2021
Price :
$50 *
At a glance
- Originator Northeastern Ohio Universities College of Medicine
- Class Antidementias; Antineoplastics; Antiparkinsonians; Antithrombotics; Cardiovascular therapies; Neuroprotectants; Nonsteroidal anti-inflammatories; Phenols; Small molecules; Stilbenes; Vasodilators
- Mechanism of Action Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer; Herpes simplex virus infections
Most Recent Events
- 21 Feb 2007 RM 1812 is available for partnering (http://www.royalmountpharma.com)
- 21 Feb 2007 Phase-I clinical trials in Colorectal cancer in United Kingdom (PO)
- 30 Jan 2007 Phase-I clinical trials in Colorectal cancer in USA (PO)